8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 11, 2026·SEC
Material company update
Oct 22, 2025·SEC
Viking Therapeutics, Inc.(VKTX)Earnings, Financials & Key Ratios
VKTX•NASDAQ
$32.28
$3.74B mkt cap·Price updated May 6, 2026
AboutViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$393M-160.9%
- Net Income-$360M-227.1%
- EPS (Diluted)-3.19-215.8%
- ROE-47.34%-164.5%
- ROIC-44.42%-125.5%
- Debt/Equity0.00-83.2%
- Interest Coverage-7023.96-337.5%
VKTX Key Insights
Viking Therapeutics, Inc. (VKTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 55.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VKTX Price & Volume
Viking Therapeutics, Inc. (VKTX) stock price & volume — 10-year historical chart
Loading chart...
VKTX Growth Metrics
Viking Therapeutics, Inc. (VKTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-268.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-260%
Return on Capital
10 Years-53.27%
5 Years-36.46%
3 Years-38.98%
Last Year-51.76%
VKTX Recent Earnings
Viking Therapeutics, Inc. (VKTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
Apr 29, 2026EPS
$1.37
Est $1.01
-35.6%
Revenue
—
Q1 2026
Feb 11, 2026EPS
$1.38
Est $0.89
-55.1%
Revenue
—
Est $2M
Q4 2025
Oct 22, 2025EPS
$0.81
Est $0.70
-15.7%
Revenue
—
Q3 2025
Jul 23, 2025EPS
$0.58
Est $0.44
-31.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.37vs $1.01-35.6% | — |
| Q1 2026 | Feb 11, 2026 | $1.38vs $0.89-55.1% | —vs $2M |
| Q4 2025 | Oct 22, 2025 | $0.81vs $0.70-15.7% | — |
| Q3 2025 | Jul 23, 2025 | $0.58vs $0.44-31.8% | — |
Based on last 12 quarters of dataView full earnings history →
VKTX Peer Comparison
Viking Therapeutics, Inc. (VKTX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TERN | 4.64B | 52.97 | -47.29 | -29.95% | 0.00 | |||
 PEPG | 127.07M | 1.85 | -0.87 | -75.73% | 0.12 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 GPCR | 2.35B | 40.84 | -17.02 | -14.55% | 0.00 | |||
 CGON | 5.74B | 68.01 | -32.70 | 254.7% | -39.85% | -22.87% | 0.01 | |
 NVO | 203.36B | 45.76 | 12.65 | 6.43% | 33.14% | 61.1% | 0.67 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 AMGN | 178.7B | 331.11 | 23.27 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare VKTX vs Peers
Viking Therapeutics, Inc. (VKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VKTX Income Statement
Viking Therapeutics, Inc. (VKTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 260K | 0 | 0 | 0 | 0 | 0 | 431K | 208K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -260K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -431K▲ 0% | -208K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | - | - | - | - | - | - |
| Operating Expenses | 19.07M | 26.16M | 32.43M | 42.66M | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M | 502M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.33M | 7.12M | 8.87M | 10.73M | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M | 48.28M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 13.74M | 19.04M | 23.56M | 31.93M | 44.98M | 54.23M | 63.81M | 101.64M | 344.95M | 453.71M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -19.07M▲ 0% | -26.16M▼ 37.2% | -32.69M▼ 24.9% | -42.66M▼ 30.5% | -55.68M▼ 30.5% | -70.36M▼ 26.4% | -100.83M▼ 43.3% | -150.92M▼ 49.7% | -393.34M▼ 160.6% | -502M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -37.72% | -37.18% | -24.95% | -30.52% | -30.52% | -26.35% | -43.31% | -49.68% | -160.63% | - |
| EBITDA | -189 | 0 | -32.43M | -42.38M | -55.39M | -70.06M | -100.53M | -150.57M | -392.91M | -501.68M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | 100% | - | -30.71% | -30.67% | -26.5% | -43.49% | -49.77% | -160.94% | -191.79% |
| D&A (Non-Cash Add-back) | 19.07M | 26.16M | 260K | 277K | 296K | 291K | 292K | 346K | 431K | 320K |
| EBIT | -18.63M | -21.5M | -25.63M | -39.39M | -55.68M | -70.36M | -100.83M | -150.92M | -393.34M | -502M |
| Net Interest Income | -1.85M | 2.71M | 6.9M | 3.13M | 685K | 1.53M | 14.93M | 40.85M | 33.7M | 29.61M |
| Interest Income | 98.14K | 3.27M | 7.05M | 3.23M | 703K | 1.59M | 15.02M | 40.94M | 33.7M | 29.64M |
| Interest Expense | 1.95M | 562K | 146K | 106K | 18K | 59K | 88K | 94K | 56K | 32K |
| Other Income/Expense | -1.51M | 4.1M | 6.91M | 3.17M | 692K | 1.49M | 14.93M | 40.96M | 33.7M | 29.66M |
| Pretax Income | -20.58M▲ 0% | -22.06M▼ 7.2% | -25.78M▼ 16.8% | -39.49M▼ 53.2% | -54.99M▼ 39.2% | -68.87M▼ 25.2% | -85.89M▼ 24.7% | -109.96M▼ 28.0% | -359.64M▼ 227.1% | -472.33M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -20.58M▲ 0% | -22.06M▼ 7.2% | -25.78M▼ 16.8% | -39.49M▼ 53.2% | -54.99M▼ 39.2% | -68.87M▼ 25.2% | -85.89M▼ 24.7% | -109.96M▼ 28.0% | -359.64M▼ 227.1% | -472.33M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -39.68% | -7.22% | -16.84% | -53.21% | -39.23% | -25.24% | -24.73% | -28.02% | -227.05% | -268.33% |
| Net Income (Continuing) | -20.58M | -22.06M | -25.78M | -39.49M | -54.99M | -68.87M | -85.89M | -109.96M | -359.64M | -472.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.79▲ 0% | -0.38▲ 51.9% | -0.36▲ 5.3% | -0.50▼ 38.9% | -0.70▼ 40.0% | -0.88▼ 25.7% | -0.91▼ 3.4% | -1.01▼ 11.0% | -3.19▼ 215.8% | -4.09▲ 0% |
| EPS Growth % | 12.22% | 51.9% | 5.26% | -38.89% | -40% | -25.71% | -3.41% | -10.99% | -215.84% | -260% |
| EPS (Basic) | -0.79 | -0.38 | -0.36 | -0.50 | -0.70 | -0.88 | -0.91 | -1.01 | -3.19 | - |
| Diluted Shares Outstanding | 25.98M | 57.58M | 71.96M | 72.6M | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M | 115.57M |
| Basic Shares Outstanding | 25.98M | 57.58M | 71.96M | 72.6M | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M | 115.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VKTX Balance Sheet
Viking Therapeutics, Inc. (VKTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 21.85M | 302.13M | 283.5M | 256.1M | 210.53M | 167.04M | 367.23M | 907.22M | 715.6M | 608.21M |
| Cash & Short-Term Investments | 20.58M | 301.52M | 275.64M | 248.39M | 202.1M | 155.49M | 362.08M | 902.61M | 705.74M | 602.96M |
| Cash Only | 8.99M | 24.78M | 8.38M | 29.12M | 26.37M | 36.63M | 55.52M | 26.68M | 165.81M | 118.12M |
| Short-Term Investments | 11.59M | 276.74M | 267.26M | 219.27M | 175.73M | 118.85M | 306.56M | 875.94M | 539.93M | 484.85M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 388.97K | 0 | 7.46M | 7.28M | 7.81M | 8.14M | 2.52M | 1.13M | 9.86M | 1.22M |
| Total Non-Current Assets | 269.61K | 179K | 755K | 399K | 134K | 1.49M | 1.26M | 1.1M | 131K | 33K |
| Property, Plant & Equipment | 0 | 0 | 598K | 321K | 25K | 1.42M | 1.13M | 1M | 85K | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 269.61K | 179K | 157K | 78K | 109K | 71K | 139K | 102K | 46K | 179K |
| Total Assets | 22.12M▲ 0% | 302.31M▲ 1266.6% | 284.26M▼ 6.0% | 256.5M▼ 9.8% | 210.66M▼ 17.9% | 168.53M▼ 20.0% | 368.49M▲ 118.7% | 908.32M▲ 146.5% | 715.73M▼ 21.2% | 608.24M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 52.19% | 1266.6% | -5.97% | -9.76% | -17.87% | -20% | 118.65% | 146.5% | -21.2% | -84.78% |
| Total Current Liabilities | 8.66M | 4.55M | 6.78M | 12.13M | 8.78M | 21.95M | 19.14M | 27.41M | 76.67M | 106.33M |
| Accounts Payable | 1.53M | 959K | 2.43M | 3.99M | 1.44M | 8.53M | 7.51M | 9.81M | 53.25M | 67.18M |
| Days Payables Outstanding | - | - | 3.41K | - | - | - | - | - | 45.1K | 57.18K |
| Short-Term Debt | 3.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 2.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.14M |
| Current Ratio | 2.52x | 66.40x | 41.83x | 21.11x | 23.98x | 7.61x | 19.19x | 33.09x | 9.33x | 9.33x |
| Quick Ratio | 2.52x | 66.40x | 41.83x | 21.11x | 23.98x | 7.61x | 19.19x | 33.09x | 9.33x | 9.33x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.98M | 12K | 360K | 29K | 0 | 1.26M | 936K | 630K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 360K | 29K | 0 | 1.26M | 936K | 630K | 0 | 728K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.66M | 4.56M | 7.14M | 12.16M | 8.78M | 23.21M | 20.07M | 28.04M | 76.67M | 106.33M |
| Total Debt | 3.45M | 0 | 662K | 359K | 29K | 1.56M | 1.26M | 1.12M | 137K | 0 |
| Net Debt | -5.54M | -24.78M | -7.71M | -28.76M | -26.34M | -35.07M | -54.26M | -25.56M | -165.67M | -118.12M |
| Debt / Equity | 0.26x | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.24x |
| Interest Coverage | -9.55x | -38.26x | -175.57x | -371.59x | -3093.44x | -1192.46x | -1145.76x | -1605.54x | -7023.96x | -15687.44x |
| Total Equity | 13.46M▲ 0% | 297.75M▲ 2111.3% | 277.12M▼ 6.9% | 244.34M▼ 11.8% | 201.88M▼ 17.4% | 145.32M▼ 28.0% | 348.42M▲ 139.8% | 880.28M▲ 152.6% | 639.06M▼ 27.4% | 501.92M▲ 0% |
| Equity Growth % | 67.41% | 2111.32% | -6.93% | -11.83% | -17.38% | -28.02% | 139.76% | 152.65% | -27.4% | -103.54% |
| Book Value per Share | 0.52 | 5.17 | 3.85 | 3.37 | 2.62 | 1.89 | 3.69 | 8.07 | 5.67 | 4.34 |
| Total Shareholders' Equity | 13.46M | 297.75M | 277.12M | 244.34M | 201.88M | 145.32M | 348.42M | 880.28M | 639.06M | 501.92M |
| Common Stock | 358 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -80.85M | -102.92M | -128.7M | -168.19M | -223.18M | -292.05M | -377.94M | -487.91M | -847.55M | -1.01B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -6.79M | -6.79M | 0 | 0 | 0 |
| Accumulated OCI | -19.77K | -423K | 12K | -54K | -549K | -1.1M | -389K | -788K | 378K | -856K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VKTX Cash Flow Statement
Viking Therapeutics, Inc. (VKTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.76M | -18.75M | -24.75M | -21.78M | -47.59M | -48.4M | -73.38M | -87.79M | -278.69M | -278.69M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -33.3% | -27.09% | -31.98% | 12.02% | -118.51% | -1.7% | -51.61% | -19.64% | -217.45% | -684.41% |
| Net Income | -20.58M | -22.06M | -25.78M | -39.49M | -54.99M | -68.87M | -85.89M | -109.96M | -359.64M | -472.33M |
| Depreciation & Amortization | 1.38M | 477K | 260K | 277K | 296K | 291K | 292K | 346K | 431K | -6.59M |
| Stock-Based Compensation | 1.45M | 2.61M | 3.74M | 5.82M | 6.1M | 8.67M | 16.75M | 29.71M | 40.82M | 39.81M |
| Deferred Taxes | -1.28M | -392K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.5M | -208K | 807K | 3.91M | 3.94M | 1.32M | -8.07M | -17.25M | -9.27M | 34.74M |
| Working Capital Changes | 1.77M | 823K | -3.78M | 7.72M | -2.93M | 10.19M | 3.55M | 9.36M | 48.98M | 64.04M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 321K | 1.2M | 5.08M | 2.61M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 263.51K | -508K | 1.47M | 1.55M | -2.54M | 7.08M | -1.02M | 2.3M | 43.44M | 59.48M |
| Cash from Investing | -1.73M | -265.73M | 7.46M | 41.57M | 37.96M | 54.75M | -179.09M | -553.37M | 341.39M | 332.33M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.73K | -265.73K | 0 | 0 | 0 | 54.75K | 0 | 0 | 0 | 291.68M |
| Cash from Financing | 22.4M | 300.27M | 887K | 950K | 6.88M | 4.16M | 271.38M | 612.46M | 76.44M | 88.17M |
| Debt Issued (Net) | -77K | -3.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 22.35M | 296.61M | 1.04M | 1.25M | 7.59M | -8.33M | 269.76M | 597.09M | 2.49M | 2.14M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -6.79M | 0 | 0 | 0 | 0 |
| Other Financing | 125.45K | 7.5M | -151K | -296K | -707K | 12.49M | 1.62M | 15.37M | 73.95M | 86.03M |
| Net Change in Cash | 5.91M▲ 0% | 15.79M▲ 167.1% | -16.4M▼ 203.9% | 20.74M▲ 226.4% | -2.75M▼ 113.2% | 10.26M▲ 473.7% | 18.88M▲ 84.0% | -28.84M▼ 252.7% | 139.13M▲ 582.4% | 80.18M▲ 0% |
| Free Cash Flow | -14.76M▲ 0% | -18.75M▼ 27.1% | -24.75M▼ 32.0% | -21.78M▲ 12.0% | -47.59M▼ 118.5% | -48.4M▼ 1.7% | -73.38M▼ 51.6% | -87.79M▼ 19.6% | -278.69M▼ 217.4% | -340.33M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -33.3% | -27.09% | -31.98% | 12.02% | -118.51% | -1.7% | -51.61% | -19.64% | -217.45% | -154% |
| FCF per Share | -0.57 | -0.33 | -0.34 | -0.30 | -0.62 | -0.63 | -0.78 | -0.81 | -2.47 | -2.47 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.85x | 0.96x | 0.55x | 0.87x | 0.70x | 0.85x | 0.80x | 0.77x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VKTX Key Ratios
Viking Therapeutics, Inc. (VKTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -191.35% | -14.18% | -8.97% | -15.15% | -24.65% | -39.67% | -34.79% | -17.9% | -47.34% | -71.31% |
| Return on Invested Capital (ROIC) | -176.97% | -13.97% | -9.04% | -13.19% | -21.35% | -36.93% | -37.4% | -19.7% | -44.42% | -44.42% |
| Debt / Equity | 0.26x | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | -9.55x | -38.26x | -175.57x | -371.59x | -3093.44x | -1192.46x | -1145.76x | -1605.54x | -7023.96x | -15687.44x |
| FCF Conversion | 0.72x | 0.85x | 0.96x | 0.55x | 0.87x | 0.70x | 0.85x | 0.80x | 0.77x | 0.72x |
VKTX SEC Filings & Documents
Viking Therapeutics, Inc. (VKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
VKTX Frequently Asked Questions
Viking Therapeutics, Inc. (VKTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Viking Therapeutics, Inc. (VKTX) grew revenue by 0.0% over the past year. Growth has been modest.
Viking Therapeutics, Inc. (VKTX) reported a net loss of $472.3M for fiscal year 2025.
Dividend & Returns
Viking Therapeutics, Inc. (VKTX) has a return on equity (ROE) of -47.3%. Negative ROE indicates the company is unprofitable.
Viking Therapeutics, Inc. (VKTX) had negative free cash flow of $340.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More VKTX
Viking Therapeutics, Inc. (VKTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates